5-Amino-4-methylindolin-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-Amino-4-methylindolin-2-one
• 英文别名: 5-amino-4-methyl-1,3-dihydroindol-2-one
• 化学式: C₉H₁₀N₂O
• mdl: MFCD11111589
• 分子量: 162.19
• InChiKey: MEZSFNSUGSIPIZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Methods of modulating tyrosine protein kinase function with indolinone compounds
  申请人：SUGEN, INC.

  公开号：US20030203901A1

  公开（公告）日：2003-10-30

  The invention relates to certain indolinone compounds, their method of synthesis, and a combinatorial library consisting of the indolinone compounds. The invention also relates to methods of modulating the function of protein tyrosine kinases using indolinone compounds and methods of treating diseases by modulating the function of protein tyrosine kinases and related signal transduction pathways.

  该发明涉及某些吲哚酮化合物，它们的合成方法以及由吲哚酮化合物组成的组合式库。该发明还涉及使用吲哚酮化合物调节蛋白酪氨酸激酶功能的方法，以及通过调节蛋白酪氨酸激酶和相关信号转导途径的功能来治疗疾病的方法。
• Indolinone combinatorial libraries and related products and methods for the treatment of disease
  申请人：Tang Cho Peng

  公开号：US20050197382A1

  公开（公告）日：2005-09-08

  The present invention relates to organic molecules capable of modulating, regulating and/or inhibiting protein kinase signal transduction. Such compounds are useful for the treatment of diseases related to unregulated protein kinase signal transduction, including cell proliferative diseases such as cancer, atherosclerosis, arthritis and restenosis and metabolic diseases such as diabetes. The present invention features indolinone compounds that potently inhibit protein kinases and related products and methods. Inhibitors specific to the FLK protein kinase can be obtained by adding chemical substituents to the 3-[(indole-3-yl)methylene]-2-indolinone, in particular at the 1′ position of the indole ring. Indolinone compounds that specifically inhibit the FLK and platelet derived growth factor protein kinases can harbor a tetrahydroindole or cyclopentano-b-pyrrol moiety. Indolinone compounds that are modified with substituents, particularly at the 5 position of the oxindole ring, can effectively activate protein kinases. This invention also features novel hydrosoluble indolinone compounds that are tyrosine kinase inhibitors and related products and methods.

  本发明涉及有机分子，能够调节、调控和/或抑制蛋白激酶信号转导。这些化合物对于治疗与不受调节的蛋白激酶信号转导相关的疾病非常有用，包括细胞增殖性疾病，如癌症、动脉粥样硬化、关节炎、再狭窄和代谢性疾病，如糖尿病。本发明涉及具有强效抑制蛋白激酶和相关产品以及方法的吲哚酮化合物。特定于FLK蛋白激酶的抑制剂可以通过在吲哚环的1'位置添加化学取代基来获得3-[(吲哚-3-基)亚甲基]-2-吲哚酮。特异性抑制FLK和血小板衍生生长因子蛋白激酶的吲哚酮化合物可以具有四氢吲哚或环戊烯基-β-吡咯基。在氧吲哚环的5位取代基的修饰下，吲哚酮化合物可以有效激活蛋白激酶。本发明还涉及新型水溶性吲哚酮化合物，它们是酪氨酸激酶抑制剂和相关产品和方法。
• Cyanoindoline derivatives as NIK inhibitors
  申请人：Janssen Pharmaceutica NV

  公开号：US11186589B2

  公开（公告）日：2021-11-30

  The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-κB-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.

  本发明涉及可用于哺乳动物治疗和/或预防的药物制剂，尤其涉及可用于治疗癌症、炎症性疾病、代谢性疾病和自身免疫性疾病等疾病的NF-κB诱导激酶（NIK-又称MAP3K14）抑制剂。本发明还涉及包含此类化合物的药物组合物，以及使用此类化合物或药物组合物预防或治疗癌症、炎症性疾病、代谢紊乱（包括肥胖和糖尿病）和自身免疫性疾病等疾病。
• HETEROCYLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE
  申请人：Sugen, Inc.

  公开号：EP1066257A2

  公开（公告）日：2001-01-10
• CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS
  申请人：Janssen Pharmaceutica NV

  公开号：EP3478673B1

  公开（公告）日：2020-09-16